Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 USD | -2.08% | -0.35% | -4.41% |
Mar. 25 | BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants | MT |
Mar. 15 | BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.41% | 86.23M | D+ | ||
+2.73% | 108B | B+ | ||
+9.59% | 103B | B+ | ||
+6.58% | 23.48B | B | ||
-12.59% | 21.93B | B+ | ||
-3.29% | 19.68B | A- | ||
-35.36% | 18.37B | A- | ||
-13.29% | 16.33B | B | ||
+4.68% | 13.72B | C+ | ||
+34.25% | 12.15B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock BioXcel Therapeutics, Inc. - Nasdaq
- Ratings BioXcel Therapeutics, Inc.